Non-Valvular Atrial Fibrillation:
Improving Detection of Undiagnosed Disease and Optimizing Treatment Strategies for Stroke Prevention: Ask the Experts Presentation (Webinar Archive)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb and Pfizer Alliance.

FACULTY

Brian T. Cryder, PharmD, BCACP
Professor of Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove, IL
Ambulatory Care Pharmacist, Chronic Disease Management
Advocate Aurora Health
Chicago, IL

Kathleen A. Lusk, PharmD, BCPS, BCCP
Associate Professor and Vice Chair, Department of Pharmacy Practice
University of the Incarnate Word Feik School of Pharmacy
Adjunct Assistant Professor, Division of Cardiology, Department of Medicine
UT Health San Antonio
San Antonio, TX

FINANCIAL DISCLOSURE

Drs. Cryder and Lusk have disclosed that they have no actual or potential conflicts of interest in relation to this program.

The clinical reviewer, Tracy Macaulay, PharmD, has disclosed that she has no actual or potential conflicts of interest related to this program.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

PHARMACY
acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-22-123-H01-P
Credits: 1.5 hour (0.15 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 00 minutes

Published

December 16, 2022

Expires

December 14, 2023

TARGET AUDIENCE

Health-system pharmacists

HOW TO OBTAIN CREDIT

During the period December 16, 2022 to December 14, 2023, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

OVERVIEW (Archived Event)

Get your questions answered by pharmacist experts!

National guidelines for the management of non-valvular AF (NVAF), which is the most common type of AF, now recommend direct-acting oral anticoagulants (DOACs) over warfarin in patients who are eligible for oral anticoagulation for stroke prevention. There are many factors to consider when choosing an anticoagulant in this population, and making evidence-based, patient-specific decisions in this arena can be challenging. Stroke risk, bleeding risk, dosing regimen/ease of adherence, drug interactions, and patient comorbidities may all play a role in the anticoagulant selection process. This interactive webinar will provide the opportunity to ask questions about current management strategies for non-valvular atrial fibrillation (NVAF). The presentation, which will afford greater opportunities to ask questions, will cover the latest science on the consequences of undiagnosed/untreated NVAF, identification strategies and risk factors, and considerations for anticoagulant selection to ensure early and appropriate NVAF treatment for optimal stroke prevention.

LEARNING OBJECTIVES:

Upon completion of this program, participants should be better able to:

  • Discuss the consequences of NVAF in patients who are undiagnosed or untreated
  • Summarize different AF screening methods and opportunities to improve AF detection
  • Differentiate between direct-acting oral anticoagulants used for NVAF and the rationale for their use in stroke prevention
  • Formulate strategies to optimize individualized anticoagulant selection and patient management to enhance treatment outcomes for NVAF

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Bristol Myers Squibb and Pfizer Alliance. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.